Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Siegfried Holding AG was founded in 1977 as a small family-owned business in Basel, Switzerland. Since then, it has grown into a leading biopharmaceutical company and is involved in research and development in the fields of oncology and endocrinology. The company is committed to bringing innovative medicines to the market in order to improve patient outcomes.
Our dream is to enable people to become more irresistibly compelling and seriously relevant!
Our vision is to be the leader in research, development and delivery of safe, effective and targeted treatments for patients suffering from cancer and endocrine diseases.
Mr. Peter A. Gehler (Chief Communications Officer)
Mr. Peter Kiechle Ph.D. (Chief Compliance Officer)
Mr. Arnoud Michael Middel (Chief HR Officer)
Dr. Luca Dalla Torre (Gen. Counsel & Sec.)
Ms. Marianne Spane (Chief Bus. Officer)
Daniel Nieper (Chief Strategy Officer)
Mr. Enno Schweinberger Ph.D. (Head Global Quality Management DS - Zofingen)
Recognition and Awards
Siegfried Holding AG has received numerous awards, including being named one of the top three pharmaceutical companies in Switzerland and one of the top twenty companies in Europe in 2016. The company was also awarded “Switzerland’s most innovative biotech company of the year” in 2018.